June 9th, 2020 (Lure, France) - The European Commission (EC) has approved, under the EU merger Regulation, the proposed acquisition of Bayer’s Animal Health Division by Elanco Animal Health. This EC decision is conditional on the divestment of several products, including the Profender® and Drontal® product families, as well as the related pipeline assets, to be acquired by Vetoquinol.
The approval of the European Commission marks an important milestone for Vetoquinol towards the completion of the acquisition and the integration of these product families into the Vetoquinol product range.
On February 12th 2020, Vetoquinol had announced the acquisition of the Profender® and Drontal® product families for the European Economic Area and the UK. The Profender® and Drontal® families of products are spot-on and tablet de-wormers for cats and dogs.
The transaction is expected to close early August 2020 and remains subject to additional regulatory approvals and customary closing conditions.
Matthieu Frechin, CEO of Vetoquinol, said "We are extremely pleased to share this major regulatory step towards the completion of the acquisition of the Profender® and Drontal® product lines. The acquisition of these two strong brands as well as the related pipeline is at the core of Vetoquinol strategy. On the one hand, they will significantly increase the size of our business and our visibility in the parasiticide segment, one of our strategic therapeutic areas. On the other hand, they will strengthen our portfolio of Essentials, the engine of our growth.”
Latest news of vetoquinol
15 Oct 2020Vetoquinol posted sales of €114.5 million for the third quarter of 2020, up 14.3% as reported compared to the same period last year. All...
VETOQUINOL, SNGTV and FARMVETSYSTEMS sign a partnership agreement to offer a common, innovative digital solution to the veterinary healthcare market.28 Sep 2020September 28th, 2020 (Paris, France) VETOQUINOL, FARMVET SYSTEMS and SNGTV have signed a partnership agreement aimed at offering a common solution...